SHANGHAI – As the probe into Glaxosmithkline plc enters a new, quieter but possibly deeper phase, the investigation has highlighted the greater oversight that drug companies can expect in the future from the most powerful regulatory bodies in the country.
SHANGHAI – The announcement that China's largest pharmaceutical company will build the country's largest biotechnology research center in Wuhan is cementing the reputation of the Chinese city as a global biotech center. China National Pharmaceutical Group Corp. (Sinopharm) plans to build the center at the Wuhan National Bioindustry Base, also known as Biolake, in the city of Wuhan in Hubei Province.
As the probe into Glaxosmithkline plc enters a new, quieter but possibly deeper phase, the investigation has highlighted the greater oversight that drug companies can expect in the future from the most powerful regulatory bodies in the country.
SHANGHAI -–The travails of Zhejiang Hangzhou Xinfu Pharma, a small Chinese biotech firm that lost money several years running, are a clear warning to investors.
SHANGHAI – A year after China introduced an amended patent law, authorities have revoked the patent on Gilead Science Inc.'s HIV/AIDS and hepatitis B drug Viread (tenofovir disoproxil fumarate).
SHANGHAI – Still avoiding discussion of its failed bid for Onyx Pharmaceuticals Inc. in June, Amgen Inc. continues to implement an ambitious Asia expansion strategy when it announced the launch of a new collaboration with Japan's Teijin Pharma Ltd. to search for new therapies for autoimmune diseases.
SHANGHAI – Still avoiding discussion of its failed bid for Onyx Pharmaceuticals Inc. in June, Amgen Inc. continues to implement an ambitious Asia expansion strategy when it announced the launch of a new collaboration with Japan's Teijin Pharma Ltd. to search for new therapies for autoimmune diseases.
SHANGHAI – A year after China introduced an amended patent law, authorities have revoked the patent on Gilead Science Inc.'s HIV/AIDS and hepatitis B drug Viread (tenofovir disoproxil fumarate).
SHANGHAI – Vowing to conduct an independent investigation and commit new resources to the case, Glaxosmithkline plc CEO Andrew Witty said the company's ongoing troubles in China are unlikely to spread to other countries.
SHANGHAI – Vowing to conduct an independent investigation and commit new resources to the case, Glaxosmithkline plc CEO Andrew Witty said the company's ongoing troubles in China are unlikely to spread to other countries.
